Clinical Trials Browser

OTHER_GOV × Erlotinib Hydrochloride × Clear all

NCT02748707 2022-04-28

ERLO-XIB

Phase 2 Unknown

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Tongue Neoplasms

NCT01470716 2022-04-06

Neoadjuvant Erlotinib for Operable Stage II or IIIA NSCLC With EGFR Mutations

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT03126799 2022-04-06

AvaTa

Phase 2 Unknown

EGFR Positive Non-small Cell Lung Cancer

NCT01320501 2016-05-13

REALME

Phase 4 Suspended

Lung Neoplasms

NCT01608841 2015-02-18

The Role of EGFR Mutations in Pancreatic Cancer Patients Receiving Gemcitabine With or Without Erlotinib

Phase 2 Unknown

Gastrointestinal

Pancreatic Neoplasms

NCT00636883 2014-01-22

GEMOX-T

Phase 2 Terminated

Gastrointestinal

Pancreatic Neoplasms

NCT00620269 2011-11-07

Induction Chemotherapy Followed by CCRT According to EGFR Mutation Status in NSCLC III

Phase 2 Unknown

Lung Neoplasms

NCT00784667 2010-11-30

Dux

Phase 2 Unknown

Gastrointestinal

Neoplasm Metastasis, Colorectal Neoplasms

NCT00268684 2006-02-28

Comparison Study of WBRT and SRS Alone Versus With Temozolomide or Erlotinib in Patients With Brain Metastases of NSCLC

Phase 3 Unknown

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis